|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...116117118119120121122123124125126...156157» |
- Enrollment change: Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France) (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=5, Completed, Sponsor: University of Virginia
N=10 --> 5
- | minocycline / Generic mfg.
Enrollment change: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 28, 2013
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
N=10 --> 5 N=200 --> 154
- New P2 trial: Vitamin D to Improve Endothelial Function in SLE (clinicaltrials.gov) - Jul 28, 2013
P2, N=32, Recruiting, Sponsor: Medical University of South Carolina
- DiaPep277 / Evotec, Amgen
Enrollment closed: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 (clinicaltrials.gov) - Jul 28, 2013
P3, N=11, Active, not recruiting, Sponsor: Rabin Medical Center
N=200 --> 154 Recruiting --> Active, not recruiting
- | minocycline / Generic mfg.
Enrollment closed: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 28, 2013
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P2 trial: HORTOCI: Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. (clinicaltrials.gov) - Jul 25, 2013
P2, N=20, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
- ||| Extavia (IFN-β-1b) / Novartis
Enrollment change: EPOC: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (clinicaltrials.gov) - Jul 24, 2013
P4, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=264 --> 200
- ||||| CNTO6785 / J&J, Fontacea
New P2 trial: An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jul 24, 2013
P2, N=250, Recruiting, Sponsor: Janssen Research & Development, LLC
- Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment change: TIV and High Dose TIV in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 24, 2013
P2, N=102, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=264 --> 200 N=200 --> 102
- |||||| Orencia (abatacept) / BMS
Enrollment open: MTX-IR: Methotrexate-Inadequate Response Autoinjector Device Sub Study (clinicaltrials.gov) - Jul 24, 2013
P3, N=120, Enrolling by invitation, Sponsor: Bristol-Myers Squibb
N=200 --> 102 Not yet recruiting --> Enrolling by invitation
- bortezomib / Generic mfg.
Enrollment open: CAD0111: Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease (clinicaltrials.gov) - Jul 24, 2013
P2, N=25, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: TIV and High Dose TIV in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 24, 2013
P2, N=102, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: SELECTION: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jul 24, 2013
P2, N=517, Completed, Sponsor: Biogen Idec
Recruiting --> Completed Active, not recruiting --> Completed
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal: A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (clinicaltrials.gov) - Jul 23, 2013
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change: A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (clinicaltrials.gov) - Jul 23, 2013
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
Not yet recruiting --> Withdrawn N=50 --> 0
- | Tavalisse (fostamatinib) / Rigel
Trial termination: OSKIRA-Asia-1X: A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 23, 2013
P2, N=115, Terminated, Sponsor: AstraZeneca
N=50 --> 0 Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- | Tavalisse (fostamatinib) / Rigel
Trial termination: OSKIRA-Asia-1: Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 23, 2013
P2, N=163, Terminated, Sponsor: AstraZeneca
Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals. Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- Humalog pen (insulin lispro) / Eli Lilly
Enrollment change: Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog (clinicaltrials.gov) - Jul 23, 2013
P1, N=13, Completed, Sponsor: Biodel
Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals. N=18 --> 13
- Biomarker, Enrollment change: A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=23, Completed, Sponsor: MedImmune LLC
N=18 --> 13 N=75 --> 23
- | Biomarker, Trial completion: A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=23, Completed, Sponsor: MedImmune LLC
N=75 --> 23 Active, not recruiting --> Completed
- Biomarker, Enrollment open: Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=60, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- Trial completion: Concentration/Meditation Limits Inflammation (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=30, Completed, Sponsor: Radboud University
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial completion: Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 21, 2013
P4, N=10, Completed, Sponsor: Fiechtner, Justus J., M.D., P.C.
Active, not recruiting --> Completed Recruiting --> Completed
- Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change: Efficacy of Islet After Kidney Transplantation (clinicaltrials.gov) - Jul 21, 2013
P3, N=24, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=48 --> 24
- ||| Enrollment open: A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System (clinicaltrials.gov) - Jul 18, 2013
P=N/A, N=300, Recruiting, Sponsor: Biomet, Inc.
N=48 --> 24 Not yet recruiting --> Recruiting
- New P2 trial: Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 18, 2013
P2, N=28, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
New P1 trial: A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 18, 2013
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
New P1 trial: JIGSAW 117: A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) (clinicaltrials.gov) - Jul 18, 2013
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche
- ||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Patient reported outcomes: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=332, Recruiting, Sponsor: Biogen Idec
- ||| Rebif (human IFN-?-1a) / EMD Serono
Enrollment open, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=306, Recruiting, Sponsor: EMD Serono
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion, Biopsy: Transient Elastography in Autoimmune Hepatitis (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=34, Completed, Sponsor: Universit
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | tacrolimus oral / Generic mfg., leflunomide / Generic mfg.
Trial termination: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients (clinicaltrials.gov) - Jul 16, 2013
P3, N=84, Terminated, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Completed Recruiting --> Terminated; Due to safety concern of active control drug
- tabalumab (LY2127399) / Eli Lilly
Enrollment change: Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 16, 2013
P3, N=8, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Terminated; Due to safety concern of active control drug N=180 --> 8
- | tacrolimus oral / Generic mfg., leflunomide / Generic mfg.
Enrollment change: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients (clinicaltrials.gov) - Jul 16, 2013
P3, N=84, Terminated, Sponsor: Astellas Pharma Inc
N=180 --> 8 N=250 --> 84
- Trial completion: Exercise in Severely Disabled Patients With MS (clinicaltrials.gov) - Jul 16, 2013
P1, N=12, Completed, Sponsor: University of Aarhus
N=250 --> 84 Recruiting --> Completed
- |||||||||| Cosentyx (secukinumab) / Novartis
New P3 trial: REASSURE-E: Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA. (clinicaltrials.gov) - Jul 15, 2013
P3, N=454, Recruiting, Sponsor: Novartis Pharmaceuticals
- | INV103 / Invion
Enrollment open: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jul 15, 2013
P1/2, N=32, Recruiting, Sponsor: Invion, Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2013
P3, N=12, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=16 --> 12
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept (clinicaltrials.gov) - Jul 15, 2013
P3, N=77, Completed, Sponsor: Amgen
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2013
P3, N=12, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=16 --> 12 Recruiting --> Active, not recruiting
- | Savella (milnacipran) / AbbVie, Pierre Fabre
Enrollment change: Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 14, 2013
P4, N=18, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting N=30 --> 18
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 14, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
N=30 --> 18 Recruiting --> Active, not recruiting
- | Savella (milnacipran) / AbbVie, Pierre Fabre
Trial completion: Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 14, 2013
P4, N=18, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting Recruiting --> Completed
- | atorvastatin / Generic mfg.
Trial completion: Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) (clinicaltrials.gov) - Jul 14, 2013
P3, N=221, Completed, Sponsor: Laura Schanberg
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: MDRS for Prevention of Nocturnal Hypoglycemia (clinicaltrials.gov) - Jul 14, 2013
P1, N=38, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: Accu-Chek Combo in Young Patients (clinicaltrials.gov) - Jul 13, 2013
P=N/A, N=15, Recruiting, Sponsor: Rabin Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Enrollment open: INSPIREt: Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jul 11, 2013
P2, N=24, Recruiting, Sponsor: Queen Mary University of London
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 11, 2013
P3, N=856, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion: Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 11, 2013
P3, N=120, Completed, Sponsor: medac GmbH
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| DiaPep277 / Evotec, Amgen
New P3 trial: DIA-AID 2: Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 (clinicaltrials.gov) - Jul 10, 2013
P3, N=300, Not yet recruiting, Sponsor: Andromeda Biotech Ltd.